PRESS RELEASE

Stockholm, Sweden, 28 January 2025

Sobi's latest haemophilia research to be presented at EAHAD 2025

Sobi® will unveil new data at the annual European Association for Haemophilia and Allied Disorders (EAHAD 2025) congress in Milan from the 4th - 7th February, 2025. Outcomes and analyses investigating the effectiveness of ALTUVOCT® and Elocta® in adults, adolescents, and children with haemophilia A will be presented, further showcasing Sobi's commitment to advancing standards of care in haemophilia.

"People with haemophilia can experience bleeding episodes that can cause pain, irreversible joint damage, and life-threatening haemorrhages," said Lydia Abad-Franch, MD, MBA, Head of Research, Development, and Medical Affairs, and Chief Medical Officer at Sobi. "At EAHAD 2025, Sobi's poster and oral presentations will demonstrate the important progress that has been made in the treatment of haemophilia A, as we continue to move the treatment paradigm towards normal haemostasis. We look forward to sharing our findings in Milan."

Key data to be presented at EAHAD 2025		
ALTUVOCT (efanesoctocog alfa) Joint with Sanofi.	Two-Year Clinical Outcomes of Once-Weekly Efanesoctocog Alfa Prophylaxis in Children with Severe Haemophilia A: Second Interim Analysis of the XTEND-ed Phase 3 Study	Oral presentation. #OR12 Session date: Friday, 07 February 2025 Presentation time: 13:45-15:15
ALTUVOCT (efanesoctocog alfa) Joint with Sanofi.	Efanesoctocog Alfa for the Perioperative Management of Patients with Severe Haemophilia A: 4 years of Experience in the XTEND Clinical Program	Oral presentation. #OR02 Session date: Friday, 07 February 2025 Presentation time: 08:30 - 10:00
ALTUVOCT (efanesoctocog alfa) Joint with Sanofi.	Clinical outcomes over 3 years of efanesoctocog alfa in adults and adolescents with severe haemophilia A: European results from the second interim analysis of XTEND-ed	Poster presentation. #PO109 Session date: Wednesday, February 5, 2025 Presentation time: 6:30 - 7:30
ALTUVOCT (efanesoctocog alfa) Joint with Sanofi.	Clinical outcomes over 2 years of efanesoctocog alfa in children with severe haemophilia A: European results from the second interim analysis of XTEND-ed	Poster presentation. # PO148 Session date: Wednesday, February 5, 2025 Presentation time: 6:30 - 7:30
ALTUVOCT (efanesoctocog alfa) Joint with Sanofi.	Treatment of Bleeding Episodes with Efanesoctocog Alfa in Adults and Adolescents with Severe Haemophilia A: Second Interim Analysis of the XTEND-ed Long-term Extension Study	Poster presentation. #PO060 Session date: Wednesday, February 5, 2025 Presentation time: 6:30 - 7:30
ALTUVOCT (efanesoctocog alfa) Joint with Sanofi.	Patient characteristics in FREEDOM, a study evaluating physical activity and joint health in patients with haemophilia A receiving efanesoctocog alfa prophylaxis	Poster presentation. #PO047 Session date: Wednesday, February 5, 2025 Presentation time: 6:30 - 7:30

Swedish Orphan Biovitrum AB (publ) (Sobi®)
Postal address SE-112 76 Stockholm, Sweden
Phone: +46 8 697 20 00 | www.sobi.com

ALTUVOCT (efanesoctocog alfa)	Assessment of treatment schedule, factor VIII trough level, and area under the curve for efanesoctocog alfa vs an extended half-life FVIII comparator: a modelling approach	Poster presentation. #PO115 Session date: Wednesday, February 5, 2025 Presentation time: 6:30 - 7:30
ALTUVOCT (efanesoctocog alfa)	Impact of a hypothetical switch to efanesoctocog alfa prophylaxis on bleeding, treatment burden and area under the curve in severe haemophilia A: Italian CHESS III cohort analysis	Poster presentation. #PO127 Session date: Welcome Reception, Wednesday, February 5, 2025 Presentation time: 6:30 - 7:30
Elocta®/Eloctate® (efmoroctocog alfa)	Real-World Effectiveness and Usage of a Recombinant Factor VIII Fc: Interim Analysis in Adults from the 48-Month Prospective, Observational A-MORE Study	Poster presentation. #PO120 Session date: Wednesday, February 5, 2025 Presentation time: 6:30 - 7:30
Elocta®/Eloctate® (efmoroctocog alfa)	Real-World Effectiveness and Usage of a Recombinant Factor VIII Fc: Interim Analysis in Children and Adolescents from the 48-Month Prospective, Observational A-MORE Study	Poster presentation. #PO079 Session date: Wednesday, February 5, 2025 Presentation time: 6:30 - 7:30

About ALTUVOCT®
ALTUVOCT (efanesoctocog alfa) [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein] (formerly BIVV001) is the first high-sustained FVIII replacement therapy with the potential to deliver near-normal factor activity levels for a significant part of the week, improving bleed protection in a once-weekly dose for people with haemophilia A. Efanesoctocog alfa builds on the established Fc fusion technology by innovatively adding a region of von Willebrand factor and XTEN® polypeptides to extend its time in circulation. It is the only therapy that has been shown to break through the von Willebrand factor ceiling, which imposes a half-life limitation on current factor VIII therapies. The European Commission granted Orphan Drug designation in June 2019 It is approved and marketed as ALTUVOCT™ by Sobi in Europe. It is approved and marketed as ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl] by Sanofi in the United States, Japan, and Taiwan.

About Elocta®/Eloctate®
Elocta®/Eloctate® (efmoroctocog alfa) is a recombinant clotting factor therapy developed for haemophilia A using Fc fusion technology to prolong circulation in the body. It is engineered by fusing factor VIII to the Fc portion of immunoglobulin G subclass 1, or IgG1 (a protein commonly found in the body), enabling Elocta to use a naturally occurring pathway to extend the time the therapy remains in the body (half-life). Elocta is manufactured using a human cell line in an environment free of animal and human additives. Elocta is approved and marketed by Sobi for the treatment of haemophilia A in the EU, the UK, Iceland, Kuwait, Liechtenstein, Norway, Saudi Arabia and Switzerland. It is approved and marketed as Eloctate® (Antihemophilic Factor [Recombinant], Fc Fusion Protein) by Sanofi in the United States, Canada Japan, Australia, New Zealand and other countries, where Sanofi has the marketing rights.

About Sobi®
Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology, and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia, and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.

Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.